NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want ...

Cassava Sciences' failed trials, limited cash for strategic pivots, and lack of clear direction create significant downside ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

NEW YORK, Jan. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during ...

Cassava Sciences Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -76.28%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment ...

Joe Edelman, a legendary biotech investor, warns that shorting industry stocks isn’t easy. He has become a billionaire, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Cassava Science provided a business update. In November 2024, Cassava reported that the topline results from the Phase 3 RETHINK-ALZ study ...

Austin-area robotic architecture firm ICON and pharmaceutical company Cassava Sciences combined to layoff over 120 workers ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates ...